Batu Biologics Recruits Vice President of Precision Oncology

Batu Biologics Recruits Dr. Vijay Mahant as the Vice President of Precision Oncology to Oversee the Personalization of ValloVax Immunogenicity

Dr. Mahant to assist with the development of screening criteria to identify patients who are most likely to receive clinical benefit from the ValloVax immunotherapy

Today, Batu Biologics announced the recruitment of Dr. Vijay Mahant to the management team in the position of Vice President of Precision Oncology. Under this role, Dr. Mahant will assist with the optimization of the clinical development of ValloVax, with a focus on identifying methods to stratify patients based on biomarkers that may be able to predict response to therapy.

Read the full article at businesswire.com

Leave a Reply

Your email address will not be published. Required fields are marked *